Congratulations Canada’s Stem Cell Network CDTRP winners!

Congratulations to the CDTRP members and their teams who were successful in the Stem Cell Network 2022 Funding Competition! Canada’s Stem Cell Network (SCN) is pleased to allocate $19.5M to support 32 projects and clinical trials across the country, with 34 partner organizations committing $22.4M of in kind or cash support.

We look forward to supporting these projects with patient, family and donor partnerships, trainee support, management resources, communication, and knowledge translation support.

Read more about the funded projects below. See the full list of awardees here.

For more information about the support the CDTRP can provide its members, please visit the grant support section of our website.
Horizon Award
  • Affiliation: University of Alberta
  • Project Title: Autologous iPSC-Islets for Personalized Diabetes Therapy: a First-in-Human Implantation and Scale-up Manufacturing
  • SCN Funds Allocated: $2,993,396
Early Career Researcher Jump-Start Award
  • Affiliation: University Health Network
  • Project Title: A Nanoparticle-based Strategy to Therapeutically Restore Regenerative Capacity in Cirrhotic Livers
  • SCN Funds Allocated: $300,000
Translation and Society Team Award
  • Affiliation: University of Regina
  • Co-Investigators: Timothy Caulfield (University of Alberta), Ubaka Ogbogu (University of Alberta)
  • Project Title: Law, Public Policy and Social License for Next-Generation Regenerative Medicine
  • SCN Funds Allocated: $704,985
What do you hope to achieve with this funding? 

“The aim of this funding grant is to therapeutically target specific cell types and molecular mechanisms that help a liver regenerate even when it is scarred, such as liver cirrhosis. This funding will help us to characterize specific cell types and molecular signatures driving fibrotic liver regeneration in mouse model, to determine the complex cellular processes and cell-cell interaction that account for regeneration in human cirrhotic livers, and finally to assess a liver-selective nanoparticle strategy targeting the Hippo pathway to help the cirrhotic liver regenerate. The ultimate goal of our project is to translate the PorphyHDL strategy, a lipoprotein-like nanoparticle combined with the siRNA of interest, to the clinic to treat patients with chronic liver disease, to treat patients with chronic liver disease, in particular once their regenerative capacity is significantly reduced.

Combining the liver-selective technology of nanoparticles with siRNA against genes of interest will provide the exciting first steps towards a novel therapeutic strategy in regenerative medicine, with the goal of improving patient survival.”

– Dr. Mamatha Bhat

What do you hope to achieve with this funding? 

“The overall objective of this project is to support development of an inclusive regulatory and governance framework that will strengthen the social license for the clinical translation of regenerative medicine. We will seek to do so by focusing on regulatory systems that support sustainable and equitable innovation and technology translation, exploring professional regulation as a governance mechanism for clinical applications of regenerative medicine, and by enhancing understanding regarding misinformation about regenerative medicine and its relationship with public trust in the field.”

– Dr. Amy Zarzeczny